Myriad Genetics, Inc. (MYGN) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Myriad Genetics, Inc. is a leading molecular diagnostic testing and precision medicine company. The company operates as a single reporting segment, offering tests across hereditary cancer, tumor profiling, prenatal health, and pharmacogenomics. The filing highlights a significant impairment event triggered by a sustained decline in market capitalization and downward forecast revisions.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $213.1 million | $211.5 million | $409.0 million | $413.7 million |
| Gross Profit | $151.8 million | $147.1 million | $286.0 million | $284.8 million |
| Gross Margin | 71.2% | 69.6% | 69.9% | 68.8% |
| Operating Loss | $(329.2) million | $(36.5) million | $(358.2) million | $(64.4) million |
| Net Loss | $(330.5) million | $(36.7) million | $(330.6) million | $(62.7) million |
| Diluted EPS | $(3.57) | $(0.41) | $(3.59) | $(0.69) |
| Cash & Equivalents | $74.4 million | $92.4 million | $74.4 million | $92.4 million |
| Total Debt (Current) | $59.4 million | $0 million | $59.4 million | $0 million |
Note: Debt figures reflect the Asset-Based Lending (ABL) facility balance at period end. Long-term debt was $0 at June 30, 2025, down from $39.6 million at year-end 2024.
Material Changes vs. Prior Period
- Impairment Charges: The company recorded a non-cash impairment charge of $316.7 million in Q2 2025, compared to $11.6 million in Q2 2024. This consisted of $234.7 million in goodwill impairment (Women's Health and Pharmacogenomics units) and $82.0 million in intangible asset impairment.
- Revenue Mix: Total revenue was flat year-over-year ($213.1M vs $211.5M). Growth in Hereditary Cancer (+$4.8M) and Prenatal (+$3.2M) was offset by declines in Pharmacogenomics (-$5.2M) and Tumor Profiling (-$1.2M).
- Pharmacogenomics Decline: Revenue in this segment dropped due to a 16% decrease in average revenue per test, driven by UnitedHealthcare's decision to stop covering certain multi-gene panel tests (including GeneSight).
- Cost Management: Cost of revenue decreased 5% year-over-year due to lower reagent costs. General and administrative expenses decreased 7% due to reduced consulting fees and amortization.
- Tax Benefit: A discrete income tax benefit of $29.4 million was recognized in the first half of 2025, primarily from the release of unrecognized tax benefits related to CARES Act refund claims.
Guidance, Outlook, and Risks
- Debt Refinancing: Subsequent to the quarter end (July 31, 2025), the company closed a new $200 million term loan facility with OrbiMed. An initial $125 million was drawn to repay the ABL facility in full. The new facility matures in 2030 and includes a minimum trailing twelve-month revenue covenant starting at $615 million in December 2025.
- Strategic Focus: Management is pivoting to focus on the Cancer Care Continuum (CCC) market, expanding prenatal offerings (FirstGene), and leveraging state biomarker laws for pharmacogenomics.
- Liquidity: Cash and cash equivalents decreased to $74.4 million. The company expects existing resources and the new credit facility to meet requirements for the next 12 months.
- Risks:
- Reimbursement Risk: Continued negative impact from UnitedHealthcare coverage changes on GeneSight revenue.
- Covenant Compliance: The new credit facility imposes strict revenue covenants; failure to meet these could trigger a default.
- Legal Proceedings: Ongoing qui tam lawsuit regarding alleged False Claims Act violations (unsealed Jan 2025); company filed a motion to dismiss in June 2025.
Investor Verification Checklist
- Impairment Assumptions: Verify the discount rates (16-17%) and revenue forecasts used in the goodwill and intangible asset impairment testing.
- UnitedHealthcare Impact: Assess the long-term revenue trajectory of the Pharmacogenomics segment given the permanent loss of coverage for GeneSight under major commercial plans.
- Debt Covenants: Monitor the company's ability to meet the new $615 million trailing twelve-month revenue covenant starting December 31, 2025.
- Cash Burn: Review operating cash flow trends, which showed a use of $29.9 million in the first half of 2025, to ensure the new term loan provides sufficient runway.
- Legal Exposure: Track the status of the qui tam lawsuit and potential insurance coverage limitations.